The obstetrician and gynecologist is rarely confronted with more serious infections than those caused by the gonococcus and the hemolytic streptococcus. Since its introduction in 1935, sulfanilamide1 has been used in the treatment of these infections, but not always with favorable results and sometimes with untoward consequences. In sepsis due to the hemolytic streptococcus, the death rate is so high that drastic though hazardous therapy is sometimes justifiable. Gonococcic infection, although frequently associated with serious or incapacitating complications, rarely causes death; so until further studies have been made, routine use of this therapy which may produce dangerous reactions is unwarranted.
Some time ago this investigation was undertaken in order to determine the efficacy of sulfanilamide therapy on gonorrhea of the female. The treatment of gynecologic and obstetric patients presented certain problems not previously encountered in the administration of the drug, namely:
The elimination of the drug in certain
ADAIR FL, HESSELTINE HC, HAC LR. AN EXPERIMENTAL STUDY OF THE BEHAVIOR OF SULFANILAMIDE. JAMA. 1938;111(9):766–770. doi:10.1001/jama.1938.02790350006003
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: